Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1858 1
1870 1
1871 2
1872 1
1881 1
1888 2
1910 1
1911 1
1919 1
1920 1
1924 1
1926 1
1930 1
1935 2
1938 2
1939 2
1945 1
1946 3
1947 5
1948 6
1949 7
1950 6
1951 7
1952 3
1953 10
1954 6
1955 5
1956 4
1957 11
1958 15
1959 14
1960 4
1961 10
1962 10
1963 11
1964 5
1965 11
1966 22
1967 22
1968 12
1969 22
1970 25
1971 29
1972 27
1973 37
1974 24
1975 28
1976 30
1977 38
1978 35
1979 37
1980 44
1981 41
1982 57
1983 65
1984 57
1985 75
1986 57
1987 80
1988 67
1989 70
1990 54
1991 86
1992 93
1993 102
1994 95
1995 102
1996 95
1997 94
1998 109
1999 159
2000 195
2001 211
2002 180
2003 216
2004 220
2005 252
2006 221
2007 228
2008 189
2009 211
2010 281
2011 320
2012 366
2013 369
2014 405
2015 362
2016 381
2017 374
2018 447
2019 465
2020 505
2021 523
2022 213
Text availability
Article attribute
Article type
Publication date

Search Results

8,538 results
Results by year
Filters applied: . Clear all
Page 1
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study.
Gainor JF, Curigliano G, Kim DW, Lee DH, Besse B, Baik CS, Doebele RC, Cassier PA, Lopes G, Tan DSW, Garralda E, Paz-Ares LG, Cho BC, Gadgeel SM, Thomas M, Liu SV, Taylor MH, Mansfield AS, Zhu VW, Clifford C, Zhang H, Palmer M, Green J, Turner CD, Subbiah V. Gainor JF, et al. Among authors: taylor mh. Lancet Oncol. 2021 Jul;22(7):959-969. doi: 10.1016/S1470-2045(21)00247-3. Epub 2021 Jun 9. Lancet Oncol. 2021. PMID: 34118197 Clinical Trial.
Endometritis.
Taylor M, Pillarisetty LS. Taylor M, et al. 2022 May 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–. 2022 May 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–. PMID: 31985918 Free Books & Documents.
Retraction Note: Tumor necrosis factor overcomes immune evasion in p53-mutant medulloblastoma.
Garancher A, Suzuki H, Haricharan S, Chau LQ, Masihi MB, Rusert JM, Norris PS, Carrette F, Romero MM, Morrissy SA, Skowron P, Cavalli FMG, Farooq H, Ramaswamy V, Jones SJM, Moore RA, Mungall AJ, Ma Y, Thiessen N, Li Y, Morcavallo A, Qi L, Kogiso M, Du Y, Baxter P, Henderson JJ, Crawford JR, Levy ML, Olson JM, Cho YJ, Deshpande AJ, Li XN, Chesler L, Marra MA, Wajant H, Becher OJ, Bradley LM, Ware CF, Taylor MD, Wechsler-Reya RJ. Garancher A, et al. Among authors: taylor md. Nat Neurosci. 2022 Jan;25(1):127. doi: 10.1038/s41593-021-00994-3. Nat Neurosci. 2022. PMID: 34907396 Free PMC article. No abstract available.
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study.
Subbiah V, Hu MI, Wirth LJ, Schuler M, Mansfield AS, Curigliano G, Brose MS, Zhu VW, Leboulleux S, Bowles DW, Baik CS, Adkins D, Keam B, Matos I, Garralda E, Gainor JF, Lopes G, Lin CC, Godbert Y, Sarker D, Miller SG, Clifford C, Zhang H, Turner CD, Taylor MH. Subbiah V, et al. Among authors: taylor mh. Lancet Diabetes Endocrinol. 2021 Aug;9(8):491-501. doi: 10.1016/S2213-8587(21)00120-0. Epub 2021 Jun 9. Lancet Diabetes Endocrinol. 2021. PMID: 34118198 Clinical Trial.
Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial.
Ho CY, Day SM, Axelsson A, Russell MW, Zahka K, Lever HM, Pereira AC, Colan SD, Margossian R, Murphy AM, Canter C, Bach RG, Wheeler MT, Rossano JW, Owens AT, Bundgaard H, Benson L, Mestroni L, Taylor MRG, Patel AR, Wilmot I, Thrush P, Vargas JD, Soslow JH, Becker JR, Seidman CE, Lakdawala NK, Cirino AL; VANISH Investigators, Burns KM, McMurray JJV, MacRae CA, Solomon SD, Orav EJ, Braunwald E. Ho CY, et al. Among authors: taylor mrg. Nat Med. 2021 Oct;27(10):1818-1824. doi: 10.1038/s41591-021-01505-4. Epub 2021 Sep 23. Nat Med. 2021. PMID: 34556856 Free PMC article. Clinical Trial.
Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.
Lee CH, Shah AY, Rasco D, Rao A, Taylor MH, Di Simone C, Hsieh JJ, Pinto A, Shaffer DR, Girones Sarrio R, Cohn AL, Vogelzang NJ, Bilen MA, Gunnestad Ribe S, Goksel M, Tennøe ØK, Richards D, Sweis RF, Courtright J, Heinrich D, Jain S, Wu J, Schmidt EV, Perini RF, Kubiak P, Okpara CE, Smith AD, Motzer RJ. Lee CH, et al. Among authors: taylor mh. Lancet Oncol. 2021 Jul;22(7):946-958. doi: 10.1016/S1470-2045(21)00241-2. Epub 2021 Jun 15. Lancet Oncol. 2021. PMID: 34143969 Clinical Trial.
Complement component 3 from astrocytes mediates retinal ganglion cell loss during neuroinflammation.
Gharagozloo M, Smith MD, Jin J, Garton T, Taylor M, Chao A, Meyers K, Kornberg MD, Zack DJ, Ohayon J, Calabresi BA, Reich DS, Eberhart CG, Pardo CA, Kemper C, Whartenby KA, Calabresi PA. Gharagozloo M, et al. Among authors: taylor m. Acta Neuropathol. 2021 Nov;142(5):899-915. doi: 10.1007/s00401-021-02366-4. Epub 2021 Sep 6. Acta Neuropathol. 2021. PMID: 34487221
8,538 results